Literature DB >> 21862876

Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.

Jing He1, Lubing Gu, Hailong Zhang, Muxiang Zhou.   

Abstract

Previous studies show that the MYCN and MDM2-p53 signal pathways are mutually regulated: MYCN stimulates MDM2 and p53 transcription, whereas MDM2 stabilizes MYCN mRNA and induces its translation. Herein, we report that the interaction between MDM2 and MYCN plays a critical role in MYCN-amplified neuroblastoma tumor cell growth and survival. Distinct from the known role that MDM2 has in regulating tumor promotion in non-MYCN-amplified neuroblastoma, in which MDM2 inhibits p53, we found that MDM2 stimulated tumor growth in MYCN-amplified neuroblastoma in a p53-independent manner. In MYCN-amplified neuroblastoma cells, enforced expression of MDM2 further enhanced MYCN expression, yet no p53 inhibition was observed by MDM2 due to upregulation of MYCN that stimulated p53 transcription. Similarly, p53 expression remained unchanged in MDM2-silenced MYCN-amplified neuroblastoma cells because MDM2 inhibition resulted in a downregulation of MYCN that decreased p53 transcription, although the MDM2-mediated degradation of p53 was reduced. Also, we found that the enforced overexpression of MDM2, or conversely, the inhibition of overexpressed endogenous MDM2, led to either a remarkable increase or decrease in tumor growth, respectively, in MYCN-amplified neuroblastoma (even though no p53 function was involved). These results suggest that p53 that is reciprocally regulated by MDM2 and MYCN is dispensable for suppression of MYCN-amplified neuroblastoma, and that the direct interaction between MDM2 and MYCN may contribute significantly to MYCN-amplified neuroblastoma growth and disease progression.
© 2011 Landes Bioscience

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862876      PMCID: PMC3218600          DOI: 10.4161/cc.10.17.17118

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  25 in total

Review 1.  Eukaryotic DNA replication: from pre-replication complex to initiation complex.

Authors:  H Takisawa; S Mimura; Y Kubota
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.

Authors:  W Lutz; M Stöhr; J Schürmann; A Wenzel; A Löhr; M Schwab
Journal:  Oncogene       Date:  1996-08-15       Impact factor: 9.867

Review 4.  Molecular biology of neuroblastoma.

Authors:  J M Maris; K K Matthay
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.

Authors:  Jason M Shohet; M John Hicks; Sharon E Plon; Susan M Burlingame; Susan Stuart; Si-Yi Chen; Malcolm K Brenner; Jed G Nuchtern
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

6.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

Authors:  R C Seeger; G M Brodeur; H Sather; A Dalton; S E Siegel; K Y Wong; D Hammond
Journal:  N Engl J Med       Date:  1985-10-31       Impact factor: 91.245

7.  Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.

Authors:  R Corvi; L Savelyeva; S Breit; A Wenzel; R Handgretinger; J Barak; M Oren; L Amler; M Schwab
Journal:  Oncogene       Date:  1995-03-16       Impact factor: 9.867

8.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

9.  Interaction between the retinoblastoma protein and the oncoprotein MDM2.

Authors:  Z X Xiao; J Chen; A J Levine; N Modjtahedi; J Xing; W R Sellers; D M Livingston
Journal:  Nature       Date:  1995-06-22       Impact factor: 49.962

10.  MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.

Authors:  L Gu; H Zhang; J He; J Li; M Huang; M Zhou
Journal:  Oncogene       Date:  2011-08-08       Impact factor: 9.867

View more
  27 in total

Review 1.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

2.  A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA.

Authors:  Kristina Heyne; Christine Winter; Fabian Gerten; Christina Schmidt; Klaus Roemer
Journal:  Cell Cycle       Date:  2013-06-28       Impact factor: 4.534

3.  Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.

Authors:  Hailong Zhang; Tao Liu; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Oncol       Date:  2015-03-24       Impact factor: 6.603

4.  Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.

Authors:  Lauren A Gillory; Jerry E Stewart; Michael L Megison; Alicia M Waters; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2015-03-14       Impact factor: 2.192

5.  MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.

Authors:  Qin Tong; Shuming Ouyang; Rui Chen; Jie Huang; Linlang Guo
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

6.  Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.

Authors:  Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto
Journal:  J Nucl Med       Date:  2017-07-26       Impact factor: 10.057

7.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

8.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

9.  miR-34a inhibits the apoptosis of MDSCs by suppressing the expression of N-myc.

Authors:  Si Chen; Anfei Huang; Huo Chen; Yi Yang; Fei Xia; Liping Jin; Jinping Zhang
Journal:  Immunol Cell Biol       Date:  2016-02-01       Impact factor: 5.126

Review 10.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.